down arrow

AgeX Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00848H1086
USD
3.47
-0.01 (-0.29%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.453.48

52 Week

3.457.90
Valuation
Technical
Day's Volume

CASH

1.5 k

Shareholding (Mar 2025)

FII

0.01%

Held by 3 FIIs

DII

98.83%

Held by 1 DIIs

Promoter

0.00%

How big is AgeX Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, AgeX Therapeutics, Inc. has a market capitalization of 51.93 million, with net sales of 0.07 million and a net profit of -7.70 million over the last four quarters. The company reported shareholder's funds of 0.64 million and total assets of 6.72 million as of Dec 24.

Market Cap: As of Jun 18, AgeX Therapeutics, Inc. has a market capitalization of 51.93 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, AgeX Therapeutics, Inc. reported net sales of 0.07 million and a net profit of -7.70 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 0.64 million and total assets of 6.72 million.

Read More

What does AgeX Therapeutics, Inc. do?

22-Jun-2025

AgeX Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for human aging, categorized as a micro-cap with a market cap of approximately $51.93 million. As of March 2025, it reported a net profit loss of $5 million and has no dividend yield.

Overview: <BR>AgeX Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of therapeutics targeting human aging, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 51.93 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -2.40 <BR>Return on Equity: -1,036.68% <BR>Price to Book: 30.53<BR><BR>Contact Details: <BR>Address: 965 Atlantic Ave Ste 101, ALAMEDA CA: 94501-1079 <BR>Tel: 1 510 6718370 <BR>Website: http://www.agexinc.com

Read More

Who are in the management team of AgeX Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of AgeX Therapeutics, Inc. includes Dr. Gregory Bailey (Independent Chairman), Dr. Michael West (CEO and Founder), and Independent Directors Dr. Annalisa Jenkins and Dr. Michael May.

As of March 2022, the management team of AgeX Therapeutics, Inc. includes Dr. Gregory Bailey, who serves as the Independent Chairman of the Board, and Dr. Michael West, who is the Chief Executive Officer, Founder, and a Director. Additionally, Dr. Annalisa Jenkins and Dr. Michael May are both Independent Directors on the board.

Read More

Is AgeX Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of May 8, 2025, AgeX Therapeutics, Inc. is considered overvalued and has deteriorated to a "does not qualify" valuation grade due to extremely low return on equity and negative financial ratios, significantly underperforming compared to its peers and the S&P 500.

As of 8 May 2025, the valuation grade for AgeX Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company is currently considered overvalued, particularly given its price-to-book value of 31.10 and negative ratios such as EV to EBIT at -2.81 and EV to EBITDA at -2.84. The return on equity (ROE) is alarmingly low at -1036.68%, reflecting severe financial distress.<BR><BR>In comparison with its peers, AgeX Therapeutics shows a stark contrast; for instance, Regulus Therapeutics, Inc. has an EV to EBITDA of -9.7830, while ARCA biopharma, Inc. stands at -0.8008. These figures suggest that AgeX is not only underperforming but also lacks the financial stability seen in its competitors. The company's stock has underperformed against the S&P 500 over various time frames, with a one-year return of -30.83% compared to the index's 10.26%, reinforcing the notion of overvaluation.

Read More

Is AgeX Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, AgeX Therapeutics, Inc. shows a neutral trend with mixed signals, as weekly indicators are bearish while daily moving averages are mildly bullish, and it has underperformed the S&P 500 with a 1-year return of -24.96%.

As of 4 September 2025, the technical trend for AgeX Therapeutics, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across different time frames. The weekly MACD and Bollinger Bands are bearish, while the daily moving averages are mildly bullish. The Dow Theory indicates a mildly bearish stance on both weekly and monthly charts. Additionally, the stock has significantly underperformed compared to the S&P 500 across multiple periods, with a 1-year return of -24.96% versus the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 49 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-3.25

stock-summary
Return on Equity

-1,149.83%

stock-summary
Price to Book

27.09

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-6 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-34.28%
0%
-34.28%
6 Months
-41.38%
0%
-41.38%
1 Year
-39.65%
0%
-39.65%
2 Years
-73.19%
0%
-73.19%
3 Years
530.91%
0%
530.91%
4 Years
-84.09%
0%
-84.09%
5 Years
-94.2%
0%
-94.2%

AgeX Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is AgeX Therapeutics, Inc. technically bullish or bearish?

As of 4 September 2025, the technical trend for AgeX Therapeutics, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across different time frames. The weekly MACD and Bollinger Bands are bearish, while the daily moving averages are mildly bullish. The Dow Theory indicates a mildly bearish stance on both weekly and monthly charts. Additionally, the stock has significantly underperformed compared to the S&P 500 across multiple periods, with a 1-year return of -24.96% versus the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-35.98%
EBIT Growth (5y)
-18.08%
EBIT to Interest (avg)
-7.64
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.40
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
4.08%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
31.10
EV to EBIT
-2.81
EV to EBITDA
-2.84
EV to Capital Employed
-20.51
EV to Sales
48.83
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-1036.68%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (1.17%)

Foreign Institutions

Held by 3 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -35.42% vs -442.86% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.50",
          "val2": "-5.80",
          "chgp": "5.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.00",
          "val2": "1.00",
          "chgp": "-200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.50",
          "val2": "-4.80",
          "chgp": "-35.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-42,807.70%",
          "val2": "0.00%",
          "chgp": "-4,280.77%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -96.88% vs 0.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -311.32% vs 150.48% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "3.20",
          "chgp": "-96.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.90",
          "val2": "-3.00",
          "chgp": "-463.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.60",
          "chgp": "-16.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "6.10",
          "val2": "8.70",
          "chgp": "-29.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.20",
          "val2": "5.30",
          "chgp": "-311.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-304,428.60%",
          "val2": "-992.40%",
          "chgp": "-30,343.62%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.10
0.00
Operating Profit (PBDIT) excl Other Income
-5.50
-5.80
5.17%
Interest
0.00
0.00
Exceptional Items
-1.00
1.00
-200.00%
Consolidate Net Profit
-6.50
-4.80
-35.42%
Operating Profit Margin (Excl OI)
-42,807.70%
0.00%
-4,280.77%
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -35.42% vs -442.86% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.10
3.20
-96.88%
Operating Profit (PBDIT) excl Other Income
-16.90
-3.00
-463.33%
Interest
0.50
0.60
-16.67%
Exceptional Items
6.10
8.70
-29.89%
Consolidate Net Profit
-11.20
5.30
-311.32%
Operating Profit Margin (Excl OI)
-304,428.60%
-992.40%
-30,343.62%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -96.88% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -311.32% vs 150.48% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About AgeX Therapeutics, Inc. stock-summary
stock-summary
AgeX Therapeutics, Inc.
Pharmaceuticals & Biotechnology
AgeX Therapeutics Inc. is a biotechnology company. The Company is focused on the development and commercialization of therapeutics targeting human aging. Its induced Tissue Regeneration (iTR) technology is based telomerase-mediated cellular immortality and regenerative biology. Its pipeline includes two cell-based, two drug-based therapeutic products, online database products and research products. The Company’s AGEX-BAT1 is its cell therapy product candidate that is being developed for the treatment of certain age-related metabolic disorders, such as Type II (adult-onset) diabetes. AGEX-VASC1 is its cell-based therapy that is designed to restore vascular support in aged ischemic tissues such as the aging heart. AGEX-iTR1547 is its drug-based formulation developed to restore regenerative potential in an array of aged tissues afflicted with degenerative disease using its proprietary iTR technology. Renelon is its iTR product candidate designed to promote scar less tissue repair.
Company Coordinates stock-summary
Company Details
965 Atlantic Ave Ste 101 , ALAMEDA CA : 94501-1079
stock-summary
Tel: 1 510 6718370
stock-summary
http://www.agexinc.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."